With regard to FABP4, previous studies demonstrated its increased concentrations in patients with CS compared with lean, but not obese subjects (13), as well as a decline in FABP4 upon UFC normalisation with twelve months of pharmacological treatment (19). This evidence concerns the gene FABP4 and Cowden syndrome 1.